Search for: [Abstract = "The examination of orphan drugs in selected countries i.e., Belgium, Denmark, England, France, Germany, Italy, Poland, Scotland, Spain, Sweden, The Netherlands, and Wales revealed that the percentage of reimbursed orphan drugs varied among the countries from the lowest in Poland to the highest in Denmark. Analysis of agreement in decision\-making regarding reimbursement of orphan drugs and HTA recommendations among analysed countries revealed that the highest, substantial agreement in reimbursement decisions was observed between Italy and Spain, and the highest agreement in recommendations was observed between England and Scotland. Study of the EMA\-issued type of authorisation of analysed orphan drugs showed that the conditional approval significantly decreased the chance for reimbursement in France, Italy, and Spain\; however the approval granted under the exceptional circumstances had similar impact only in Germany. Analysis of impact of the type of the disease treated with the specific orphan drugs revealed that the drugs for metabolic diseases were more likely to be approved under exceptional circumstances, but had lesser odds for being conditionally approved when compared to other drugs for non\-metabolic and non\-oncologic diseases. The opposite was observed for drugs used in treatment of patients with oncologic diseases. In\-depth study of reimbursement decision\-making pr"]

Number of results: 1